AXSOME THERAPEUTICS INC's ticker is AXSM and the CUSIP is 05464T104. A total of 172 filers reported holding AXSOME THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.32 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $260,628,617 | -3.1% | 3,729,126 | -0.4% | 0.01% | 0.0% |
Q2 2023 | $268,954,231 | +25.1% | 3,742,753 | +7.4% | 0.01% | +20.0% |
Q1 2023 | $215,001,060 | -18.4% | 3,485,750 | +2.0% | 0.01% | -28.6% |
Q4 2022 | $263,601,648 | +89.9% | 3,417,628 | +9.8% | 0.01% | +75.0% |
Q3 2022 | $138,835,000 | +29.4% | 3,111,500 | +11.0% | 0.00% | +33.3% |
Q2 2022 | $107,322,000 | -3.9% | 2,802,138 | +3.8% | 0.00% | 0.0% |
Q1 2022 | $111,730,000 | +10.1% | 2,699,490 | +0.5% | 0.00% | +50.0% |
Q4 2021 | $101,463,000 | +15.9% | 2,685,622 | +1.1% | 0.00% | 0.0% |
Q3 2021 | $87,572,000 | -50.3% | 2,656,885 | +1.6% | 0.00% | -50.0% |
Q2 2021 | $176,350,000 | +19.6% | 2,614,145 | +0.4% | 0.00% | 0.0% |
Q1 2021 | $147,424,000 | -31.5% | 2,603,740 | -1.4% | 0.00% | -33.3% |
Q4 2020 | $215,167,000 | +16.6% | 2,641,074 | +2.0% | 0.01% | 0.0% |
Q3 2020 | $184,460,000 | +15.9% | 2,588,911 | +33.9% | 0.01% | 0.0% |
Q2 2020 | $159,093,000 | +94.0% | 1,933,560 | +38.7% | 0.01% | +100.0% |
Q1 2020 | $81,997,000 | -41.8% | 1,393,806 | +2.3% | 0.00% | -40.0% |
Q4 2019 | $140,770,000 | +452.3% | 1,361,944 | +8.2% | 0.01% | +400.0% |
Q3 2019 | $25,487,000 | -14.1% | 1,259,255 | +9.3% | 0.00% | 0.0% |
Q2 2019 | $29,671,000 | +131.2% | 1,152,285 | +27.8% | 0.00% | 0.0% |
Q1 2019 | $12,832,000 | +1243.7% | 901,787 | +166.2% | 0.00% | – |
Q4 2018 | $955,000 | -51.7% | 338,704 | -40.9% | 0.00% | – |
Q3 2018 | $1,976,000 | +6.4% | 572,701 | -1.4% | 0.00% | – |
Q2 2018 | $1,858,000 | +42.2% | 580,605 | +8.8% | 0.00% | – |
Q1 2018 | $1,307,000 | -52.4% | 533,679 | +9.0% | 0.00% | – |
Q4 2017 | $2,743,000 | +17.7% | 489,752 | +16.6% | 0.00% | – |
Q3 2017 | $2,331,000 | +53.3% | 419,922 | +51.8% | 0.00% | – |
Q2 2017 | $1,521,000 | +16.6% | 276,615 | -17.4% | 0.00% | – |
Q1 2017 | $1,305,000 | -29.0% | 334,745 | +23.0% | 0.00% | – |
Q4 2016 | $1,837,000 | -8.2% | 272,189 | +7.3% | 0.00% | – |
Q3 2016 | $2,000,000 | +7.0% | 253,749 | +2.3% | 0.00% | – |
Q2 2016 | $1,869,000 | +4.3% | 247,937 | +19.0% | 0.00% | – |
Q1 2016 | $1,792,000 | – | 208,424 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ALETHEA CAPITAL MANAGEMENT, LLC | 1,132,645 | $37,332,000 | 32.86% |
MORGAN JESS S & CO INC | 113,430 | $3,739,000 | 2.47% |
Fairmount Funds Management LLC | 187,598 | $6,183,000 | 2.25% |
IRIDIAN ASSET MANAGEMENT LLC/CT | 1,423,653 | $46,924,000 | 1.43% |
WMS Partners, LLC | 250,000 | $8,240,000 | 1.21% |
Beck Bode, LLC | 102,127 | $3,366,000 | 0.94% |
RTW INVESTMENTS, LP | 1,616,497 | $53,280,000 | 0.80% |
MPM BioImpact LLC | 110,155 | $3,631,000 | 0.56% |
Endurant Capital Management LP | 52,048 | $1,716,000 | 0.39% |
Bellevue Group AG | 752,945 | $24,817,000 | 0.25% |